NCT06589804 2026-03-18
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
National Cancer Institute (NCI)
Phase 3 Recruiting
Clinical Trials
3 trialsNCT05721755 2026-03-05
Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck
Eastern Cooperative Oncology Group
Phase 3 Active not recruiting
NCT07441681 2026-03-02
Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin
NRG Oncology
Phase 3 Not yet recruiting